Galectin Therapeutics Inc - ESG Rating & Company Profile powered by AI
This Disclosure rating covers seventeen United Nations Sustainable Development Goals including: 'Gender Equality', 'Decent Work & Economic Growth' and 'Life below Water'. This page contains a Q&A section for Galectin Therapeutics Inc. Check the bottom of the webpage for potential risks for Galectin Therapeutics Inc based on sector, location and size.
Galectin Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.0; made up of an environmental score of 0.0, social score of 2.7 and governance score of 3.4.
2.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 2110 | Yabao Pharmaceutical Group Co Ltd | 2.1 | Medium |
| 2110 | scPharmaceuticals Inc | 2.1 | Medium |
| 2150 | Galectin Therapeutics Inc | 2.0 | Medium |
| 2150 | BNC Korea Co Ltd | 2.0 | Medium |
| 2150 | BTG Ltd | 2.0 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Galectin Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Galectin Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Galectin Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Galectin Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Galectin Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Galectin Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Galectin Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Galectin Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Galectin Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Galectin Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Galectin Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Galectin Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Galectin Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Galectin Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Galectin Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Galectin Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Galectin Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Galectin Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.